探讨氢吗啡酮预防小儿腹腔镜疝修补术后早期疼痛的有效剂量

注册号:

Registration number:

ChiCTR2600116860 

最近更新日期:

Date of Last Refreshed on:

2026-01-15 17:04:55 

注册时间:

Date of Registration:

2026-01-15 00:00:00 

注册号状态:

补注册

Registration Status:

Retrospective registration

注册题目:

探讨氢吗啡酮预防小儿腹腔镜疝修补术后早期疼痛的有效剂量

Public title:

To explore the effective dose of hydromorphone in preventing early postoperative pain after laparoscopic hernia repair in children.

注册题目简写:

English Acronym:

研究课题的正式科学名称:

探究氢吗啡酮预防小儿腹腔镜疝修补术后早期疼痛的有效剂量

Scientific title:

To explore the effective dose of hydromorphone in preventing early postoperative pain after laparoscopic hernia repair in children

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

张欣然 

研究负责人:

赫颖 

Applicant:

Xinran Zhang 

Study leader:

Ying He 

申请注册联系人电话:

Applicant telephone:

+86 189 9024 5118

研究负责人电话:

Study leader's
telephone:

+86 136 3364 6828

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

2532179109@qq.com

研究负责人电子邮件:

Study leader's E-mail:

13633646828@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

黑龙江省哈尔滨市松北区爱婴大街998号

研究负责人通讯地址:

黑龙江省哈尔滨市松北区爱婴大街998号

Applicant address:

No. 998 Aiying Street, Songbei District, Harbin City, Heilongjiang Province

Study leader's address:

No. 998 Aiying Street, Songbei District, Harbin City, Heilongjiang Province

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

哈尔滨医科大学附属第六医院

Applicant's institution:

The Sixth Affiliated Hospital of Harbin Medical University

研究负责人所在单位:

哈尔滨医科大学附属第六医院

Affiliation of the Leader:

The Sixth Affiliated Hospital of Harbin Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

LC2025-037

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

哈尔滨医科大学附属第六医院医学伦理委员会

Name of the ethic committee:

Ethics Committee of the Sixth Affiliated Hospital of Harbin Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2025-07-17 00:00:00

伦理委员会联系人:

许芝林

Contact Name of the ethic committee:

Zhilin Xu

伦理委员会联系地址:

黑龙江省哈尔滨市松北区爱婴大街998号

Contact Address of the ethic committee:

No. 998 Aiying Street, Songbei District, Harbin City, Heilongjiang Province

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 136 0368 1238

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

哈尔滨医科大学附属第六医院

Primary sponsor:

The Sixth Affiliated Hospital of Harbin Medical University

研究实施负责(组长)单位地址:

黑龙江省哈尔滨市松北区爱婴大街998号

Primary sponsor's address:

No. 998 Aiying Street, Songbei District, Harbin City, Heilongjiang Province

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

黑龙江

市(区县):

哈尔滨

Country:

China

Province:

Heilongjiang

City:

Harbin

单位(医院):

哈尔滨医科大学附属第六医院

具体地址:

黑龙江省哈尔滨市松北区爱婴大街998号

Institution
hospital:

The Sixth Affiliated Hospital of Harbin Medical University

Address:

No. 998 Aiying Street, Songbei District, Harbin City, Heilongjiang Province

经费或物资来源:

Source(s) of funding:

none

研究疾病:

无  

Target disease:

none

研究疾病代码:

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

其它 

Study phase:

N/A

研究设计:

单臂 

Study design:

Single arm 

研究目的:

使用改良的Dixon序贯法探索氢吗啡酮用于预防小儿腹腔镜疝修补术后早期疼痛的最佳有效剂量,减轻患儿术后疼痛,提高苏醒质量,提供更为舒适的手术体验  

Objectives of Study:

To explore the optimal dose of hydromorphone for preventing early pain after laparoscopic hernia repair in children by using modified Dixon sequential method, so as to reduce postoperative pain, improve recovery quality and provide more comfortable surgical experience.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

1.对本研究使用的药物过敏; 2.近期有上呼吸道感染者; 3.术前 24 h 应用镇静或镇痛药物; 4.有神经系统疾病、精神疾病、心肺疾病病史.

Exclusion criteria:

1. Allergic to the medications used in this study; 2. Recently had an upper respiratory tract infection; 3. Used sedatives or analgesics within 24 hours before surgery; 4. History of neurological, psychiatric, or cardiopulmonary diseases.

研究实施时间:

Study execute time:

From 2025-08-20 00:00:00 To 2026-08-20 00:00:00  

征募观察对象时间:

Recruiting time:

From 2025-08-30 00:00:00 To 2025-12-30 00:00:00

干预措施:

Interventions:

组别:

试验组

样本量:

32

Group:

Experimental group

Sample size:

干预措施:

对手术患儿进行常规麻醉,在手术停气腹时以5ug/kg氢吗啡酮作为起始剂量进行镇痛,根据FLACC评分判断镇痛成功或者失败,失败则下一患者增加0.5ug/kg;相反,成功则下一患者减少0.5ug/kg

干预措施代码:

Intervention:

For pediatric patients undergoing surgery, routine anesthesia was administered. During the cessation of pneumoperitoneum, hydromorphone was used as the initial dose for analgesia at 5 μg/kg. The success or failure of analgesia was assessed based on the FLACC score. If unsuccessful, the next patient's dose was increased by 0.5 μg/kg; conversely, if successful, the next patient's dose was decreased by 0.5 μg/kg

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

黑龙江 

市(区县):

哈尔滨 

Country:

China

Province:

Heilongjiang

City:

Harbin

单位(医院):

哈尔滨医科大学附属第六医院 

单位级别:

三甲 

Institution
hospital:

The Sixth Affiliated Hospital of Harbin Medical University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

FLACC疼痛评分

指标类型:

主要指标

Outcome:

FLACC Pain Score

Type:

Primary indicator

测量时间点:

麻醉苏醒后0分钟,苏醒后5分钟,10分钟,20分钟,30分钟

测量方法:

Measure time point of outcome:

0 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes after anesthesia awakening

Measure method:

指标中文名:

血压

指标类型:

次要指标

Outcome:

Blood pressure

Type:

Secondary indicator

测量时间点:

麻醉苏醒后0分钟,5分钟,10分钟,20分钟,30分钟

测量方法:

Measure time point of outcome:

0 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes after anesthesia awakening

Measure method:

指标中文名:

心率

指标类型:

次要指标

Outcome:

Heart rate

Type:

Secondary indicator

测量时间点:

麻醉苏醒后0分钟,5分钟,10分钟,20分钟,30分钟

测量方法:

Measure time point of outcome:

0 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes after anesthesia awakening

Measure method:

指标中文名:

血氧

指标类型:

次要指标

Outcome:

Oxyhemoglobin saturation

Type:

Secondary indicator

测量时间点:

麻醉苏醒后0分钟,5分钟,10分钟,20分钟,30分钟

测量方法:

Measure time point of outcome:

0 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes after anesthesia awakening

Measure method:

指标中文名:

m-YPAS术前焦虑评分

指标类型:

次要指标

Outcome:

the modified yale preoperative anxiety scale

Type:

Secondary indicator

测量时间点:

患儿进入手术室前

测量方法:

Measure time point of outcome:

Before the child enters the operating room

Measure method:

指标中文名:

儿童麻醉苏醒期谵妄评分

指标类型:

次要指标

Outcome:

pediatric anesthesia emergence delirium scale

Type:

Secondary indicator

测量时间点:

麻醉苏醒后0分钟,5分钟,10分钟,20分钟,30分钟

测量方法:

Measure time point of outcome:

0 minutes, 5 minutes, 10 minutes, 20 minutes, 30 minutes after anesthesia awakening

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

结束

/Completed

年龄范围:

Participant age:

最小 Min age years
最大 Max age years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

Randomization Procedure (please state who generates the random number sequence and by what method):

None

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

对研究者和参试者设盲

Blinding:

Blinding of researchers and participants

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

将会在试验完成后6个月内在 www.medresman.org.cn 上传数据

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

The data will be uploaded to www.medresman.org.cn within 6 months after the completion of the trial

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

病例记录表;电子采集和管理系统

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

EDC; CRF

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2026-01-15 17:04:48